Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
5.974,07
0,73%
NASDAQ
19.764,89
0,00%
Bitcoin
94.030,74
-0,70%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Biogen Inc (BIIB) Biogen Inc (BIIB) Notizie

Biogen Inc

BIIB
149,38
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 13:40:55
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
09/12/202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202422:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202416:33EDGAR2Form 144 - Report of proposed sale of securities
05/12/202400:31PRNUS"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early..
28/11/202401:31PRNUS"LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's..
19/11/202407:00GLOBEDapirolizumab Pegol Phase 3 Data Presented at the American..
14/11/202419:29PRNUSEisai Receives Positive Opinion from the CHMP in the..
14/11/202417:23GLOBEEisai Receives Positive Opinion from the CHMP in the..
07/11/202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/11/202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202400:30GLOBEEisai Presents Data on Benefits of Long-Term Administration..
30/10/202421:45EDGAR2Form 8-K - Current report
30/10/202421:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
30/10/202411:55EDGAR2Form 8-K - Current report
30/10/202411:37IHMARKETNEWSUS Futures Rise as Tech Earnings Drive Market Optimism; Oil..
29/10/202423:00GLOBEBiogen and Neomorph Announce Multi-Target Research..
29/10/202413:00GLOBEBiogen Appoints Daniel Quirk, MD, as Chief Medical Officer
28/10/202413:30GLOBEMichael McDonnell, Executive Vice President and Chief..
27/10/202402:15GLOBEBiogen Presents Positive Results from Phase 2 IGNAZ Study of..
24/10/202413:30GLOBEBiogen to Present New Data at the Clinical Trials on..
22/10/202413:30GLOBEBiogen Announces Late Breaker and New Data Presentations at..
09/10/202413:30GLOBEBiogen Receives U.S. FDA Breakthrough Therapy Designation..
08/10/202413:30GLOBENew Higher Dose Nusinersen Efficacy and Safety Data..
08/10/202401:08EDGAR2Form 3 - Initial statement of beneficial ownership of..
24/9/202407:00GLOBEUCB and Biogen Announce Positive Topline Results From Phase..
12/9/202413:31EDGAR2Form 8-K - Current report
12/9/202413:30GLOBEBiogen Board Appoints Two New Independent Directors
05/9/202412:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/9/202413:30GLOBEBiogen Announces Positive Topline Results from Study of..
03/9/202419:00EDGAR2Form 144 - Report of proposed sale of securities
22/8/202411:10PRNUSLeqembi® (lecanemab) Authorized for Early Alzheimer's..
17/8/202400:40EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/8/202422:30EDGAR2Form 8-K - Current report
01/8/202422:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202412:55EDGAR2Form 8-K - Current report
31/7/202415:00PRNUSAlcyone Therapeutics Announces Continued Enrollment Approval..
30/7/202423:15GLOBENew Clinical Data Demonstrates Three Years of Continuous..
30/7/202423:00PRNUSNew Clinical Data Demonstrates Three Years of Continuous..
30/7/202413:30GLOBEBiogen, Beckman Coulter and Fujirebio to Collaborate on..
26/7/202413:20GLOBEUpdate on Regulatory Review of Lecanemab for Early..
24/7/202412:30BWSage Therapeutics and Biogen Announce Topline Results from..
17/7/202411:45PRNUSThe Gross Law Firm Notifies Biogen Inc. Investors of a Class..
16/7/202410:00PRNUSBiogen Inc Sued for Securities Law Violations - Contact the..
12/7/202411:45PRNUSBiogen Inc. Sued for Securities Law Violations - Investors..
03/7/202411:45PRNUSJuly 22, 2024 Deadline: Contact The Gross Law Firm to Join..
02/7/202415:16GLOBEBiogen Completes Acquisition of Human Immunology Biosciences
28/6/202412:50IHMARKETNEWSNike Stock Drops 14% in Pre-Market; Nokia Acquires Infinera..
28/6/202411:45PRNUSBIIB LAWSUIT ALERT: The Gross Law Firm Notifies Biogen Inc...
28/6/202401:39GLOBE“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s..
25/6/202411:45PRNUSClass Action Filed Against Biogen Inc. (BIIB) Seeking..
Apertura: Min: Max:
Chiusura: 149,38

La tua Cronologia

NASDAQ
BIIB
Biogen
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network